Video

Dr. Borgen on Surgical Versus Medical Treatment of Breast Cancer

Patrick I. Borgen, MD, chair, Department of Surgery, head, Brooklyn Cancer Center, Maimonides Medical Center, compares the efficacy of surgical versus medical treatment of patients with breast cancer.

Patrick I. Borgen, MD, chair, Department of Surgery, head, Brooklyn Cancer Center, Maimonides Medical Center, compares the efficacy of surgical versus medical treatment of patients with breast cancer.

Although breast cancer has been thought of as a surgical disease for the last several decades, it has evolved to a more medical disease, Borgen explains. This is due to several competing factors, including earlier diagnosis, class prediction through genomic profiling, better characterization of disease, and targeted therapies, and a change in sequencing therapies.

A significant number of patients with breast cancer now begin their course of treatment with medicine, Borgen says. Such therapies have been shown to sterilize locoregional disease in select patients. Today, researchers have a greater understanding regarding the strength of blocking estrogen and endocrine therapies. If applied correctly, these novel agents will be able to achieve superb locoregional control, says Borgen.

<<<

View more from the 2015 CFS Annual Meeting

Related Videos
Sagar D. Sardesai, MBBS
DB-12
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP